Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has shared an announcement.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received approval from the National Medical Products Administration for a clinical trial of SHR-2173 Injection. This approval marks a significant step in the company’s drug development pipeline, potentially enhancing its market position and offering new opportunities for growth in the pharmaceutical sector.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$78.00 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, focusing on the development and production of innovative drugs. The company operates in the healthcare industry, with a market focus on pharmaceuticals and medical products.
Average Trading Volume: 5,741,310
Current Market Cap: HK$380.5B
See more insights into 1276 stock on TipRanks’ Stock Analysis page.